SCHEMBL2004648

SCHEMBL2004648

O=C(O)c1cc2cccc(O)c2[nH]1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.63
TDP1 Q9NUW8 2/20 0.63
HSD17B10 Q99714 4/20 0.62
HPGD P15428 3/20 0.62
ALDH1A1 P00352 3/20 0.62
MEN1 O00255 1/20 0.62
USP2 O75604 1/20 0.62
KMT2A Q03164 1/20 0.62
APEX1 P27695 2/20 0.59
DAO P14920 2/20 0.55
MAPT P10636 1/20 0.55
SRD5A2 P31213 1/20 0.55
GRIN2D O15399 2/20 0.50
GRIN2A Q12879 2/20 0.50
GRIN2B Q13224 2/20 0.50
GRIN2C Q14957 2/20 0.50
GRIN3B O60391 1/20 0.50
GRIN1 Q05586 1/20 0.50
GRIN3A Q8TCU5 1/20 0.50
GPR35 Q9HC97 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17136028 0.83 HSD17B10 (0.64) KDM4ETDP1HSD17B10HPGDALDH1A1
SCHEMBL11035155 0.81 HSD17B10 (0.62) KDM4ETDP1HSD17B10HPGDALDH1A1
SCHEMBL2042234 0.80 NSD2 (0.66) KDM4EHSD17B10HPGDALDH1A1MEN1
SCHEMBL3722103 0.80 HSD17B10 (0.60) KDM4ETDP1HSD17B10HPGDALDH1A1
SCHEMBL13770170 0.80 HPGD (0.60) KDM4ETDP1HSD17B10HPGDALDH1A1
SCHEMBL3632164 0.80 HSD17B10 (0.60) KDM4ETDP1HSD17B10HPGDALDH1A1
SCHEMBL1145013 0.80 HPGD (0.60) KDM4ETDP1HSD17B10HPGDALDH1A1
SCHEMBL1144741 0.80 HPGD (0.60) KDM4ETDP1HSD17B10HPGDALDH1A1
SCHEMBL10509208 0.80 XDH (0.50) KDM4ETDP1DAOGRIN2DGRIN2A
SCHEMBL10506723 0.79 HPGD (0.49) KDM4ETDP1HSD17B10HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115701440-A Polyimide composite film, preparation method thereof and electronic equipment 华为技术有限公司 2023-02-10 CN claimed
CN-110643032-B Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance 厦门赛诺邦格生物科技股份有限公司 2022-01-28 CN claimed
CN-110643032-A Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance 厦门赛诺邦格生物科技股份有限公司 2020-01-03 CN claimed
CN-106967213-B Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance 厦门赛诺邦格生物科技股份有限公司 2019-11-05 CN claimed
US-20260060959-A1 FORMULATIONS WITH REDUCED OXIDATION GENENTECH INC (US) 2026-03-05 US disclosed
US-20230181533-A1 FORMULATIONS WITH REDUCED OXIDATION GENENTECH INC (US) 2023-06-15 US disclosed
US-11596620-B2 Formulations with reduced oxidation F. HOFFMANN-LA ROCHE AG (CH) 2023-03-07 US disclosed
CN-115701440-A Polyimide composite film, preparation method thereof and electronic equipment 华为技术有限公司 2023-02-10 CN disclosed
US-11324827-B2 Multifunctionalized polyethylene glycol derivative and preparation method therefor XIAMEN SINOPEG BIOTECH CO., LTD. (CN) 2022-05-10 US disclosed
US-11267825-B2 Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) AICURIS GMBH & CO. KG (DE) 2022-03-08 US disclosed
US-20220047711-A1 PHOTOCROSSLINKING PEPTIDES FOR SITE SPECIFIC CONJUGATION TO FC-CONTAINING PROTEINS GENENTECH, INC. (US) 2022-02-17 US disclosed
CN-110643032-B Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance 厦门赛诺邦格生物科技股份有限公司 2022-01-28 CN disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 US disclosed
EP-2049520-A2 INDOLE COMPOUNDS Ironwood Pharmaceuticals, Inc. (US) 2009-04-22 EP disclosed
WO-2008019357-A2 INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. (US) 2008-02-14 WO disclosed
US-4835175-A Indole derivatives pharmaceutical preparations based thereon, and β-receptor stimulation therewith SCHERING AKTIENGESELLSCHAFT (DE) 1989-05-30 US disclosed
EP-0062919-B1 INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING AKTIENGESELLSCHAFT (DE) 1986-07-30 EP disclosed
EP-0062919-A1 Indole derivatives, process for their preparation and pharmaceutical compositions containing them SCHERING AKTIENGESELLSCHAFT (DE) 1982-10-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260060959-A1 FORMULATIONS WITH REDUCED OXIDATION LPO, SET, PTMS KDM4E 1738/4885TDP1 4559/4885HSD17B10 1774/4885
US-11596620-B2 Formulations with reduced oxidation PRDX5, PRDX3, LPO KDM4E 3145/4885TDP1 3432/4885HSD17B10 472/4885
US-20220047711-A1 PHOTOCROSSLINKING PEPTIDES FOR SITE SPECIFIC CONJUGATION TO FC-CONTAINING PROTEINS FCGR2A, FCGR3B, DNPEP KDM4E 4325/4885TDP1 3373/4885HSD17B10 3056/4885
US-20230181533-A1 FORMULATIONS WITH REDUCED OXIDATION PRDX5, PRDX3, LPO KDM4E 3145/4885TDP1 3432/4885HSD17B10 472/4885
US-11324827-B2 Multifunctionalized polyethylene glycol derivative and preparation method therefor HDGF, F11, F12 KDM4E 4115/4885TDP1 4223/4885HSD17B10 1914/4885
US-20090264653-A1 USEFUL INDOLE COMPOUNDS FAAH, FAAH2, AANAT KDM4E 2232/4885TDP1 1782/4885HSD17B10 548/4885
US-11267825-B2 Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) HCCS, BRD4, IDO2 KDM4E 578/4885TDP1 3811/4885HSD17B10 1826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.